Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12058
Title: A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.
Austin Authors: Lau, David K ;Andrews, Miles C;Turner, Natalie;Azad, Arun A;Davis, Ian D;Cebon, Jonathan S 
Affiliation: aLudwig Institute for Cancer Research - Austin Branch, Joint Ludwig-Austin Medical Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Health bEastern Health Clinical School, Monash University, Victoria, Australia
Issue Date: 1-Apr-2014
Publication information: Melanoma Research; 24(2): 144-9
Abstract: We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)≥2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16%) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.
Gov't Doc #: 24463460
URI: https://ahro.austin.org.au/austinjspui/handle/1/12058
DOI: 10.1097/CMR.0000000000000036
Journal: Melanoma research
URL: https://pubmed.ncbi.nlm.nih.gov/24463460
Type: Journal Article
Subjects: Adult
Aged
Aged, 80 and over
Antineoplastic Agents.adverse effects.therapeutic use
Disease-Free Survival
Female
Humans
Imidazoles.adverse effects.therapeutic use
Male
Melanoma.drug therapy.pathology
Middle Aged
Neoplasm Staging
Oximes.adverse effects.therapeutic use
Prognosis
Retrospective Studies
Skin Neoplasms.drug therapy.pathology
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.